Search

Search Constraints

You searched for: Author/Creator Joly, F.

Search Results

1. 2554 Clinical outcome of initially metastatic hormone sensitive prostate cancer (HSPC) in real life population from a single center: Comparison with initially metastatic HSPC patients included in the GETUG-AFU 15 trial. (September 2015)

2. 2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer. (September 2015)

3. 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). (September 2015)

4. 2705 The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO): How this organization changed management over the time for rare cancers. (September 2015)

5. 2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC). (September 2015)

6. 2740 Independent review committee assessment of Fagotti carcinomatosis score from 8 laparoscopic images: Ancillary analysis of ANTHALYA, a randomized, open-label, phase II study assessing the efficacy and safety of bevacizumab addition to neoadjuvant therapy for women with ovarian, tubal or peritoneal adenocarcinoma, initially unresectable. (September 2015)

7. 2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU). (September 2015)

8. 2766 Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Data from the ANTHALYA trial. (September 2015)

9. 2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting. (September 2015)

10. A multi-national survey of experience and attitudes towards commencing home parenteral nutrition for patients with advanced cancer. (February 2022)